MOS
ACRS icon

MGO One Seven’s Aclaris Therapeutics ACRS Stock Holding History

MGO One Seven’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$3K Hold
180
– – ﹤0.01% 1416
2017
Q4 		$4K Buy
+180
New +$4.38K ﹤0.01% 1346

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

MGO One Seven's ACRS Position: Q1 2018 in Review

MGO One Seven held its Aclaris Therapeutics (ACRS) position steady in Q1 2018 at 180 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1416.

MGO One Seven first reported a position in ACRS in Q4 2017 and has held it in 2 quarters since. The position peaked at $4K in Q4 2017. 100 funds tracked by Wall St. Rank hold ACRS as of Q1 2018.

  • MGO One Seven held 180 shares of Aclaris Therapeutics worth $3K as of Q1 2018.
  • MGO One Seven left its Aclaris Therapeutics share count unchanged in Q1 2018.
  • Aclaris Therapeutics made up ﹤0.01% of MGO One Seven's portfolio in Q1 2018, its #1416 holding.
  • MGO One Seven first reported a position in Aclaris Therapeutics in Q4 2017 and has held it in 2 quarters since.
  • MGO One Seven's Aclaris Therapeutics position peaked at $4K in Q4 2017.
  • 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2018.

Based on MGO One Seven's 13F filing for Q1 2018, filed 15 May 2018.